2014 ESC WGT/EHRA/EAPCI/ACCA Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary or Valve Interventions | Heart Rhythm Society

2014 ESC WGT/EHRA/EAPCI/ACCA Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary or Valve Interventions

The Heart Rhythm Society endorsed the document in June 2014.

August 26, 2014This document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions is a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, the European Heart Rhythm Association (EHRA), the European Association of Percutaneous Cardiovascular Interventions (EAPCI), and the European Association of Acute Cardiac Care (ACCA).


 See 2018 EHRA/ESC WGT/EAPCI/ACCA Joint European Consensus Document on the Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Cardiovascular Interventions.

HRS Endorsed / Affirmed
Atrial Arrhythmias
Atrial Fibrillation

In 2010, the European Society of Cardiology (ESC) Working Group on Thrombosis published a consensus document, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Coronary Intervention (EAPCI), to address the management aspects of this complex clinical scenario. This was followed by a North American consensus document, which had many similarities in management approaches. Since 2010, substantial changes are now evident in stroke prevention in AF, with the introduction of NOACs and greater attention to quality of anticoagulation control as reflected by average time in the therapeutic range (TTR) of the international normalized ratio.

For this update, the Working Group on Thrombosis of the ESC convened a Task Force, with representation from EHRA, EAPCI, and the Acute Cardiovascular Care Association (ACCA), endorsed by the Heart Rhythm Society (HRS) and the Asia Pacific Heart Rhythm Society (APHRS), with the remit to comprehensively review the published evidence available since the 2010 document, to publish a joint consensus document on the optimal antithrombotic therapy management in AF patients presenting with ACS and/or undergoing percutaneous coronary or valve interventions and to provide up-to-date recommendations for use in clinical practice.